Jump to content

Covid-19: Razvoj vakcine, imunitet i primena medikamenata

bey
bey
in Covid-19 Coronavirus

Featured Replies

COVID-19: men create more antibodies after asymptomatic infections and keep them for longer – new research

https://theconversation.com/covid-19-men-create-more-antibodies-after-asymptomatic-infections-and-keep-them-for-longer-new-research-151387

 

-----------------------------------------------------------------------------------------------------------------------------

 

The researchers found durable immune responses in the majority of people studied. Antibodies against the spike protein of SARS-CoV-2, which the virus uses to get inside cells, were found in 98% of participants one month after symptom onset. As seen in previous studies, the number of antibodies ranged widely between individuals. But, promisingly, their levels remained fairly stable over time, declining only modestly at 6 to 8 months after infection.

Virus-specific B cells increased over time. People had more memory B cells six months after symptom onset than at one month afterwards. Although the number of these cells appeared to reach a plateau after a few months, levels didn’t decline over the period studied.

Levels of T cells for the virus also remained high after infection. Six months after symptom onset, 92% of participants had CD4+ T cells that recognized the virus. These cells help coordinate the immune response. About half the participants had CD8+ T cells, which kill cells that are infected by the virus.

As with antibodies, the numbers of different immune cell types varied substantially between individuals. Neither gender nor differences in disease severity could account for this variability. However, 95% of the people had at least 3 out of 5 immune-system components that could recognize SARS-CoV-2 up to 8 months after infection.

“Several months ago, our studies showed that natural infection induced a strong response, and this study now shows that the responses last,” Weiskopf says. “We are hopeful that a similar pattern of responses lasting over time will also emerge for the vaccine-induced responses.”

https://www.nih.gov/news-events/nih-research-matters/lasting-immunity-found-after-recovery-covid-19

 

----------------------------------------------------------------------------------------------------------------------------

 

https://www.healthline.com/health-news/how-long-does-immunity-last-after-covid-19-what-we-know#How-natural-immunity-works-after-COVID-19-develops

zivija Y

    • Haha 1

     

     

     

     

     

     

     

     

     

    1QH7EXe.png

     

     

     

    myuGRT8.png

     

    • +1 1
    • Hvala 1

    Ohrabrujuće za Fajzer: "no B.1.351 cases 14+ days post 2nd dose", dakle svi su bili između 7 (minimum po definiciji pune efikasnosti u studiji) i 14 dana posle druge doze, što ukazuje na to da se efikasnost Fajzerove vakcine za tu varijantu sporije razvija, ali ipak na kraju razvije.

    Edited by vememah

    https://www.nytimes.com/2021/04/13/us/politics/johnson-johnson-vaccine-blood-clots-fda-cdc.html?campaign_id=60&emc=edit_na_20210413&instance_id=0&nl=breaking-news&ref=cta&regi_id=115687409&segment_id=55454&user_id=fb895a06ca0f60593f115b193427f13a

    Quote

    U.S. Calls for Pause on Johnson & Johnson Vaccine After Clotting Cases

    The Food and Drug Administration and the Centers for Disease Control will stop using the vaccine at federal sites and urge states to do so as well while they investigate the safety issues.

     

    • Hvala 1

    Jos ce na kraju biti da je "rajfajzen" najbolja vakcina :fantom:

    • +1 1
    Jos ce na kraju biti da je "rajfajzen" najbolja vakcina fantom.gif
    bice, zato shto je chista i nova tehnologija, kao prvo. a na to mozda i bolje vode rat protiv konkurencije. a verovatno oba.

    sent from bubamoto


    •
    • +1 2

    Kaze Bikovic da je ova Afisa navodno ozbiljan medij

    Quote

    Doduše, postotak zaštite vakcinom Sinovak varira među različitim zemljama, počevši od Turske gde je ona veća od 80% do Brazila i Srbije gde ima efikasnost od oko 50%. 

    I sad kako ja da verujem ostatku teksta kad u njemu stoji ovakva glupost. Možda je hteo da kaže da postoje neki preliminarni podaci da je efikasnost Sinofarm vakcine u Srbiji 50%, ali tako važnu informaciju bi morao mnogo jasnije da kaže.

     

    • +1 1
    On 13.4.2021. at 13:54, gospa buba said:

    bice, zato shto je chista i nova tehnologija, kao prvo. a na to mozda i bolje vode rat protiv konkurencije. a verovatno oba.

    sent from bubamoto

     

     

    Vektorske izgleda da imaju odredjene probleme dok mRnk i kineska: u principu se "kineska" cini kompletnijom jer organizam uci na kompletnom uzorku dok mRnk gadja specificno. Sira slika jeste otpornija na promene (sojevi), veci je tu problem kakva je sama tehnologija izrade u pitanju i sta su tu kinezi stavljali i koliko. Plus nema papira :)

     

    Idealna bi bila vakcina na bazi umrtvljenog virusa i koja dolazi negde sa zapada :fantom:

    To postoji, pravi je Valneva, ali još nije započela 3. fazu.

     

     

     

    Go to topic listing